داروسازی کوثر
دکوثر | Stocks - Tehran Stock Exchange (TSE)
داروهای شیمیایی و گیاهی
Sector:
داروهای شیمیایی و گیاهی
Market Type:
Stocks
Status:
Authorized
Last Price: 19,910 2.97
Close Price: 19,980
Income Statement
AGM
Interim
2026/04/26 Fiscal Year 2025/12/2112 Month | 2025/08/06 Fiscal Year 2025/03/2012 Month | 2024/07/07 Fiscal Year 2024/03/1912 Month | ||
|---|---|---|---|---|
Revenue from Services & Sales | 7.836 Trillion | 15.813 Trillion | 11.722 Trillion | |
Total Revenues | 7.836 Trillion | 15.813 Trillion | 11.722 Trillion | |
Cost of Goods Sold | 8.785 Trillion | 12.156 Trillion | 7.87 Trillion | |
Gross Profit | -948.523 Billion | 3.657 Trillion | 3.852 Trillion | |
General & Administrative Expenses | 750.204 Billion | 1.369 Trillion | 728.84 Billion | |
Net Operating Income & Expenses | -108.057 Billion | -44.477 Billion | -69.062 Billion | |
Operating Profit (Loss) | -1.807 Trillion | 2.244 Trillion | 3.054 Trillion | |
Profit Before Tax | 1.044 Trillion | 455.443 Billion | 2.276 Trillion | |
Tax | - | 72.423 Billion | 331.048 Billion | |
Net Profit (Loss) After Tax | 1.044 Trillion | 383.02 Billion | 1.927 Trillion | |
Retained Earnings at Beginning of Period | 2.018 Trillion | 3.45 Trillion | 1.69 Trillion | |
Prior-Year Adjustments | - | -841.575 Billion | - | |
Prior-Year Tax | - | - | 17.791 Billion | |
Approved Dividends — Prior Year AGM | -39.1 Billion | -193.8 Billion | -102 Billion | |
Capital Decrease (Increase) from Accumulated Losses (Retained Earnings) | -1.7 Trillion | - | - | |
Allocable Profit | 1.323 Trillion | 2.798 Trillion | 3.515 Trillion | |
Legal Reserve | 52.191 Billion | - | 65.304 Billion | |
Approved Dividends — Current Year | 105.4 Billion | 39.1 Billion | 193.8 Billion | |
Retained Earnings at End of Period | 1.165 Trillion | 2.759 Trillion | 3.256 Trillion |